Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings (CPHI) has disclosed Convertible Debt for 2 consecutive years, with $4.8 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Convertible Debt changed N/A year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Jun 2022, changed N/A, and an annual FY2021 reading of $5.2 million, changed N/A over the prior year.
  • Convertible Debt was $4.8 million for Q2 2022 at China Pharma Holdings, down from $5.0 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $5.2 million in Q4 2021 and bottomed at $4.8 million in Q2 2022.